Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer

SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Cypher Genomics, Inc., the genome informatics company, announced today the appointment of J. Patrick Ravenel as chief technology officer. Ravenel has more than 20 years of enterprise software and systems experience and a proven track record of designing and architecting solutions for Fortune 500 companies.

"Patrick has been recognized as a top designer and architect of enterprise class software and systems and is known industry-wide for delivering innovative products that operate at scale and securely integrate with partners, including in the health care community," said Ashley Van Zeeland, Ph.D., co-founder and CEO of Cypher Genomics. "We look forward to Patrick's expertise in security and big data management to deliver robust genome interpretation technology to our clinical and industry partners."

Ravenel will help advance Cypher's Mantis^TM, genome interpretation software as a service offering, and Coral^TM, a biomarker discovery service. Designed for pharmaceutical companies, clinical laboratories and to support population genomics efforts, Cypher's fast, accurate and robust genome interpretation and analysis technologies facilitate differentiated molecular tests, efficient clinical trials and enable precision therapeutic decisions. 

J. Patrick Ravenel is a major contributor to the design, development and deployment of high-performance distributed computing solutions. His career has focused on high performance financial trading, commercial electronic data interchange (EDI), security, compliance and analytic systems. He was previously vice president of software development at MedImpact Healthcare Systems. Prior to MedImpact, he had successful exits (both acquisition and IPO) as a co-founder and a director in the areas of security and distributed transactional caching environments. In addition to his published papers, articles and book contributions, Mr. Ravenel has four patents in information security and automated compliance management. He holds a B.A. in applied mathematics and scientific programming from the University of California, San Diego. 

About Cypher Genomics
Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics' market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use and pharmaceutical companies to discover biomarkers from whole genome sequence data in sample sizes typical of early stage drug development studies. Through Mantis^TM, the genome interpretation software as a service offering, and Coral^TM, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. Cypher Genomics is located in San Diego, California.

For more information about Cypher Genomics, visit www.cyphergenomics.com and follow us on Twitter @cyphergenomics.

SOURCE Cypher Genomics, Inc.